Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Evidence for facultative protocarnivory in Capsella bursa-pastoris seeds.

Roberts HR, Warren JM, Provan J.

Sci Rep. 2018 Jul 4;8(1):10120. doi: 10.1038/s41598-018-28564-x.

2.

Progressive improvement in wound healing with increased therapy in haemophilia B mice.

Monroe DM, Hoffman M, Roberts HR, Hedner U.

Haemophilia. 2013 Nov;19(6):926-32. doi: 10.1111/hae.12220. Epub 2013 Jul 23.

PMID:
23879625
3.

β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.

Smartt HJ, Greenhough A, Ordóñez-Morán P, Talero E, Cherry CA, Wallam CA, Parry L, Al Kharusi M, Roberts HR, Mariadason JM, Clarke AR, Huelsken J, Williams AC, Paraskeva C.

Gut. 2012 Sep;61(9):1306-14. doi: 10.1136/gutjnl-2011-300817. Epub 2011 Nov 14.

PMID:
22082586
4.

Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation.

Roberts HR, Smartt HJ, Greenhough A, Moore AE, Williams AC, Paraskeva C.

Carcinogenesis. 2011 Nov;32(11):1741-7. doi: 10.1093/carcin/bgr210. Epub 2011 Sep 16.

PMID:
21926111
5.

10th Novo Nordisk Symposium on Haemostasis Management--introduction.

Roberts HR.

Haemophilia. 2010 May;16 Suppl 3:1-2. doi: 10.1111/j.1365-2516.2010.02251.x. No abstract available.

PMID:
20586793
6.

HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.

Moore AE, Greenhough A, Roberts HR, Hicks DJ, Patsos HA, Williams AC, Paraskeva C.

Carcinogenesis. 2009 Oct;30(10):1796-804. doi: 10.1093/carcin/bgp183. Epub 2009 Jul 28.

PMID:
19638428
7.

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A.

Carcinogenesis. 2009 Mar;30(3):377-86. doi: 10.1093/carcin/bgp014. Epub 2009 Jan 9. Review.

PMID:
19136477
8.

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.

Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall J, Ferran JM, Ljung RC; Novoseven (F7HAEM-1505) Investigators.

Haemophilia. 2008 May;14(3):466-75. doi: 10.1111/j.1365-2516.2008.01654.x. Epub 2008 Feb 12. Erratum in: Haemophilia. 2008 May;14(3):670.

PMID:
18282155
9.

Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia.

McDonald AG, Yang K, Roberts HR, Monroe DM, Hoffman M.

Blood. 2008 Feb 15;111(4):2046-8. Epub 2007 Nov 30.

PMID:
18055866
10.

Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B.

McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM.

J Thromb Haemost. 2007 Aug;5(8):1577-83.

11.

Fathers of modern coagulation.

Monroe DM, Hoffman M, Roberts HR.

Thromb Haemost. 2007 Jul;98(1):3-5. No abstract available.

PMID:
17597981
12.

Vitamin K supplementation during oral anticoagulation: concerns.

Stafford DW, Roberts HR, Vermeer C.

Blood. 2007 Apr 15;109(8):3607; author reply 3607-8. No abstract available.

PMID:
17409344
13.

Contributions to the evolution of knowledge about hereditary hemorrhagic disorders.

Roberts HR.

Cell Mol Life Sci. 2007 Mar;64(5):517-21. No abstract available.

PMID:
17256091
14.

Novel therapeutic agents in the management of hemorrhage and thrombosis.

Kempton CL, Harvey RD 3rd, Roberts HR.

Cardiovasc Hematol Agents Med Chem. 2006 Oct;4(4):319-34. Review.

PMID:
17073609
15.

Cutaneous wound healing is impaired in hemophilia B.

Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM.

Blood. 2006 Nov 1;108(9):3053-60. Epub 2006 Jul 6.

PMID:
16825491
16.

Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.

Allen GA, Hoffman M, Roberts HR, Monroe DM.

Br J Haematol. 2006 Aug;134(3):314-9. Epub 2006 Jun 20.

PMID:
16787497
17.

A cell-based model of thrombin generation.

Roberts HR, Hoffman M, Monroe DM.

Semin Thromb Hemost. 2006 Apr;32 Suppl 1:32-8. Review.

PMID:
16673264
18.

Thrombin generation in vascular tissue.

Pathak A, Zhao R, Monroe DM, Roberts HR, Sheridan BC, Selzman CH, Stouffer GA.

J Thromb Haemost. 2006 Jan;4(1):60-7.

19.

High dose factor VIIa improves clot structure and stability in a model of haemophilia B.

Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M.

Br J Haematol. 2005 Dec;131(5):645-55.

PMID:
16351642
20.

Hemophilia care in the 21st century.

Kempton CL, Escobar MA, Roberts HR.

Clin Adv Hematol Oncol. 2004 Nov;2(11):733-40. Review. No abstract available.

PMID:
16170890
21.

Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?

White GC 2nd, Kempton CL, Grimsley A, Nielsen B, Roberts HR.

J Thromb Haemost. 2005 Aug;3(8):1676-81. Review.

22.

Gene therapy for hemophilia?

White GC 2nd, Roberts HR.

J Thromb Haemost. 2005 Jun;3(6):1312. No abstract available.

23.

A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects.

Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E.

Blood Coagul Fibrinolysis. 2005 Jun;16(4):259-66.

PMID:
15870545
24.

Uncertain times for research on hemophilia and allied disorders.

Mannucci PM, Roberts HR.

J Thromb Haemost. 2005 Mar;3(3):423. No abstract available.

25.

Feline polycystic kidney disease is linked to the PKD1 region.

Young AE, Biller DS, Herrgesell EJ, Roberts HR, Lyons LA.

Mamm Genome. 2005 Jan;16(1):59-65.

PMID:
15674734
26.

Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations.

Kempton CL, Hoffman M, Roberts HR, Monroe DM.

Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):861-6. Epub 2005 Jan 13.

PMID:
15653564
27.

Recombinant factor VIIa: how safe is the stuff?

Roberts HR.

Can J Anaesth. 2005 Jan;52(1):8-11. English, French. No abstract available.

PMID:
15625249
28.

More information on patients with factor XI deficiency.

Roberts HR, Escobar M, Monroe DM.

Anesthesiology. 2004 Nov;101(5):1253-4. No abstract available.

PMID:
15505483
29.

Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets.

Gabriel DA, Li X, Monroe DM 3rd, Roberts HR.

J Thromb Haemost. 2004 Oct;2(10):1816-22.

30.

Recombinant factor VIIa: a general hemostatic agent? Yes.

Roberts HR.

J Thromb Haemost. 2004 Oct;2(10):1691-4. No abstract available.

31.

The use of recombinant factor VIIa in the treatment of bleeding disorders.

Roberts HR, Monroe DM, White GC.

Blood. 2004 Dec 15;104(13):3858-64. Epub 2004 Aug 24. Review. Erratum in: Blood. 2005 Mar 15;105(6):2257.

PMID:
15328151
32.

Current concepts of hemostasis: implications for therapy.

Roberts HR, Monroe DM, Escobar MA.

Anesthesiology. 2004 Mar;100(3):722-30. Review.

PMID:
15108990
33.

Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system.

Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM.

J Thromb Haemost. 2004 Mar;2(3):402-13.

34.

Safety profile of recombinant factor VIIa.

Roberts HR, Monroe DM 3rd, Hoffman M.

Semin Hematol. 2004 Jan;41(1 Suppl 1):101-8. Review.

PMID:
14872430
35.

Monitoring coagulation and the clinical effects of recombinant factor VIIa.

Gabriel DA, Carr M, Roberts HR.

Semin Hematol. 2004 Jan;41(1 Suppl 1):20-4. Review.

PMID:
14872416
36.

Choice of replacement therapy for hemophilia.

Roberts HR.

J Thromb Haemost. 2003 Mar;1(3):595. No abstract available.

37.

Oscar Ratnoff: his contributions to the golden era of coagulation research.

Roberts HR.

Br J Haematol. 2003 Jul;122(2):180-92. No abstract available.

PMID:
12846885
38.

Hantavirus transmission: potential role of ectoparasites.

Houck MA, Qin H, Roberts HR.

Vector Borne Zoonotic Dis. 2001 Spring;1(1):75-9.

PMID:
12653138
39.

Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.

Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd.

Can J Anaesth. 2002 Dec;49(10):S7-14. Review.

PMID:
12546000
40.

Mechanism of action of high-dose factor VIIa: points of agreement and disagreement.

Monroe DM, Roberts HR.

Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):8-9; discussion 10. Review. No abstract available.

PMID:
12524217
41.

Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk.

Wolberg AS, Monroe DM, Roberts HR, Hoffman M.

Blood. 2003 Apr 15;101(8):3008-13. Epub 2002 Dec 27.

PMID:
12506014
42.

Platelets and thrombin generation.

Monroe DM, Hoffman M, Roberts HR.

Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1381-9. Review.

PMID:
12231555
43.

Overview of anticoagulant drugs for the future.

Moll S, Roberts HR.

Semin Hematol. 2002 Jul;39(3):145-57. Review.

PMID:
12124677
44.

Platelet-dependent action of high-dose factor VIIa.

Hoffman M, Monroe DM, Roberts HR.

Blood. 2002 Jul 1;100(1):364-5; author reply 365. No abstract available.

PMID:
12096717
45.

Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces.

Oliver JA, Monroe DM, Church FC, Roberts HR, Hoffman M.

Blood. 2002 Jul 15;100(2):539-46.

PMID:
12091346
46.

Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo.

Gui T, Lin HF, Jin DY, Hoffman M, Straight DL, Roberts HR, Stafford DW.

Blood. 2002 Jul 1;100(1):153-8.

PMID:
12070021
47.

Recombinant factor VIIa (Novoseven) and the safety of treatment.

Roberts HR.

Semin Hematol. 2001 Oct;38(4 Suppl 12):48-50. Review.

PMID:
11735111
48.

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures.

Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U.

Haemophilia. 2001 Sep;7(5):517-22.

PMID:
11554944
49.

The dysfibrinogenaemias.

Roberts HR, Stinchcombe TE, Gabriel DA.

Br J Haematol. 2001 Aug;114(2):249-57. Review. No abstract available.

PMID:
11529842
50.

Supplemental Content

Loading ...
Support Center